VIEKIRA PAK (COPACKAGED) Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Viekira Pak (copackaged), and what generic alternatives are available?
Viekira Pak (copackaged) is a drug marketed by Abbvie and is included in one NDA. There are seventeen patents protecting this drug.
This drug has six hundred and eighteen patent family members in fifty-four countries.
The generic ingredient in VIEKIRA PAK (COPACKAGED) is dasabuvir sodium; ombitasvir, paritaprevir, ritonavir. Additional details are available on the dasabuvir sodium; ombitasvir, paritaprevir, ritonavir profile page.
DrugPatentWatch® Generic Entry Outlook for Viekira Pak (copackaged)
Viekira Pak (copackaged) was eligible for patent challenges on December 19, 2018.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 18, 2033. This may change due to patent challenges or generic licensing.
There have been ten patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for VIEKIRA PAK (COPACKAGED)
International Patents: | 618 |
US Patents: | 17 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Patent Applications: | 22 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VIEKIRA PAK (COPACKAGED) |
DailyMed Link: | VIEKIRA PAK (COPACKAGED) at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VIEKIRA PAK (COPACKAGED)
Generic Entry Date for VIEKIRA PAK (COPACKAGED)*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for VIEKIRA PAK (COPACKAGED)
US Patents and Regulatory Information for VIEKIRA PAK (COPACKAGED)
VIEKIRA PAK (COPACKAGED) is protected by seventeen US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VIEKIRA PAK (COPACKAGED) is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting VIEKIRA PAK (COPACKAGED)
Formulations of pyrimidinedione derivative compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HCV INFECTION USING DASABUVIR
Anti-infective agents and uses thereof
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
Solid pharmaceutical dosage form
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Solid pharmaceutical dosage form
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Macrocyclic hepatitis C serine protease inhibitors
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Methods for treating HCV
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
Methods for treating HCV
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
Anti-infective agents and uses thereof
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
Macrocyclic hepatitis C serine protease inhibitors
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR
Methods for treating HCV
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
Methods for treating HCV
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
Solid compositions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Anti-viral compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Anti-viral compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HCV INFECTION USING OMBITASVIR
Compositions and methods for treating HCV
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR
Anti-infective agents and uses thereof
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HCV INFECTION USING DASABUVIR
Formulations of pyrimidinedione derivative compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HCV INFECTION USING DASABUVIR
Expired US Patents for VIEKIRA PAK (COPACKAGED)
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | ⤷ Try a Trial | ⤷ Try a Trial |
Abbvie | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | ⤷ Try a Trial | ⤷ Try a Trial |
Abbvie | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | ⤷ Try a Trial | ⤷ Try a Trial |
Abbvie | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VIEKIRA PAK (COPACKAGED)
When does loss-of-exclusivity occur for VIEKIRA PAK (COPACKAGED)?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 13330993
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 2015008927
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 88883
Estimated Expiration: ⤷ Try a Trial
China
Patent: 4853752
Estimated Expiration: ⤷ Try a Trial
Patent: 9260207
Estimated Expiration: ⤷ Try a Trial
Eurasian Patent Organization
Patent: 8481
Estimated Expiration: ⤷ Try a Trial
Patent: 2913
Estimated Expiration: ⤷ Try a Trial
Patent: 1590752
Estimated Expiration: ⤷ Try a Trial
Patent: 1791354
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 08808
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 66635
Estimated Expiration: ⤷ Try a Trial
Patent: 15534985
Estimated Expiration: ⤷ Try a Trial
Patent: 18065858
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 15004973
Estimated Expiration: ⤷ Try a Trial
Singapore
Patent: 201503051Q
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering VIEKIRA PAK (COPACKAGED) around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 20150008151 | SOLID COMPOSITIONS | ⤷ Try a Trial |
Denmark | 2468285 | ⤷ Try a Trial | |
Ukraine | 89220 | СПОСОБ ЛЕЧЕНИЯ ВИЧ/СПИДА ПУТЕМ ПРИЕМА БЕЗ ПИЩИ ИЛИ В УСЛОВИЯХ ГОЛОДАНИЯ ТВЕРДОГО ФАРМАЦЕВТИЧЕСКОГО ДОЗИРОВАННОГО СОСТАВА ИНГИБИТОРА ВИЧ-ПРОТЕАЗЫ;СПОСІБ ЛІКУВАННЯ ВІЛ/СНІДУ ШЛЯХОМ ПРИЙОМУ БЕЗ ЇЖІ АБО В УМОВАХ ГОЛОДУВАННЯ ТВЕРДОГО ФАРМАЦЕВТИЧНОГО ДОЗОВАНОГО СКЛАДУ ІНГІБІТОРА ВІЛ-ПРОТЕАЗИ (METHOD FOR TREATMENT OF HIV/AIDS BY ADMINISTRATION OF SOLID PHARMACEUTICAL DOSAGE FORMULATION COMPRISING A HIV PROTEASE INHIBITOR IN FASTED STATE) | ⤷ Try a Trial |
Japan | 2020059696 | 抗ウィルス化合物 (ANTI-VIRAL COMPOUNDS) | ⤷ Try a Trial |
Ecuador | SP14012622 | COMPUESTOS ANTIVIRALES | ⤷ Try a Trial |
Eurasian Patent Organization | 022891 | ПРИМЕНЕНИЕ МАКРОЦИКЛИЧЕСКИХ ИНГИБИТОРОВ СЕРИНОВЫХ ПРОТЕАЗ ГЕПАТИТА С (USE OF MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VIEKIRA PAK (COPACKAGED)
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2692346 | LUC00038 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: PIBRENTASVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/17/1213 20170728 |
2203431 | 38/2015 | Austria | ⤷ Try a Trial | PRODUCT NAME: DASABUVIR ODER EIN SALZ DAVON, EINSCHLIESSLICH DASABUVIR-NATRIUM-MONOHYDRAT; REGISTRATION NO/DATE: EU/1/14/983 20150115 |
2340029 | 15C0021 | France | ⤷ Try a Trial | PRODUCT NAME: PARITAPREVIR DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/14/982 20150119 |
2340029 | 92667 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: PARITAPREVIR, OU UN SEL OU ESTER PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE (VIEKIRAX). FIRST REGISTRATION: 20150119 |
2692346 | 299 50017-2017 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: PIBRENTASVIR VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/17/1213 20170728 |
2340029 | C02340029/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: PARITAPREVIR; REGISTRATION NO/DATE: SWISSMEDIC 65301 25.11.2014 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |